Danaher Corporation (NYSE:DHR) Receives $233.61 Consensus Price Target from Brokerages

Danaher Corporation (NYSE:DHR) has been assigned a consensus rating of “Moderate Buy” from the twenty-five ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $233.5217.

A number of brokerages have issued reports on DHR. Citigroup assumed coverage on shares of Danaher in a research report on Tuesday, May 26th. They set a “buy” rating and a $230.00 price objective on the stock. Argus cut their target price on shares of Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a research note on Friday, April 24th. Wells Fargo & Company reduced their price target on shares of Danaher from $240.00 to $212.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 22nd. Robert W. Baird decreased their price target on shares of Danaher from $251.00 to $249.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Finally, Weiss Ratings lowered shares of Danaher from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, June 29th.

Institutional Investors Weigh In On Danaher

Hedge funds have recently made changes to their positions in the company. Elevated Capital Advisors LLC bought a new stake in shares of Danaher during the 4th quarter valued at $26,000. Hilton Head Capital Partners LLC bought a new position in shares of Danaher in the 4th quarter worth about $27,000. Clal Insurance Enterprises Holdings Ltd lifted its position in Danaher by 71.6% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock valued at $29,000 after acquiring an additional 53 shares during the period. JPL Wealth Management LLC purchased a new position in Danaher during the 3rd quarter valued at about $25,000. Finally, Main Street Group LTD bought a new stake in Danaher during the first quarter worth about $25,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Trading Up 0.4%

NYSE DHR traded up $0.77 on Thursday, hitting $194.39. The company’s stock had a trading volume of 403,954 shares, compared to its average volume of 4,329,813. The firm has a market cap of $137.59 billion, a P/E ratio of 37.59, a PEG ratio of 2.52 and a beta of 0.79. Danaher has a 52-week low of $160.93 and a 52-week high of $242.80. The company’s 50-day simple moving average is $179.01 and its 200 day simple moving average is $200.34. The company has a current ratio of 1.87, a quick ratio of 1.52 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last posted its earnings results on Monday, April 20th. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.12. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The firm had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same period in the previous year, the firm earned $1.88 earnings per share. The business’s revenue was up 3.7% compared to the same quarter last year. Research analysts predict that Danaher will post 8.44 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Friday, June 26th. Danaher’s dividend payout ratio (DPR) is presently 30.95%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.